Examkin

Question

Difficulty: HardNon-Systematic and Credit Risks

An investor holds a concentrated position in senior unsecured debt issued by a mid-sized biotechnology firm. Following the unexpected rejection of the company's leading therapeutic candidate by regulatory authorities, credit rating agencies downgraded the firm's debt from investment grade to speculative grade. Concurrently, broader macroeconomic pressures caused benchmark interest rates to increase across the economy. Which of the following statements regarding the risks affecting this investor's bond position are correct?

  1. The elevated risk of default stemming from the regulatory rejection represents a non-systematic risk that can be mitigated through asset diversification.Answer
  2. B
    The decline in bond prices caused by rising benchmark interest rates is a form of credit risk unique to this biotechnology issuer.
  3. The credit rating downgrade directly increases the issuer-specific credit risk premium demanded by the secondary market, independent of systematic rate changes.Answer
  4. D
    Systematic price declines in fixed-income markets resulting from macroeconomic rate hikes can be eliminated completely by spreading capital across diverse corporate bond issuers.

Answer

The statement identifying default risk from regulatory rejection as a diversifiable non-systematic risk, and the statement noting that the credit rating downgrade reflects issuer-specific credit risk independent of systemic rate movements, are both correct.
The correct statements correctly classify the failure of the biotechnology firm's drug candidate and the subsequent credit downgrade as non-systematic credit/business risks unique to the issuer. Because these factors are firm-specific, they can be mitigated through asset diversification, and the credit downgrade reflects an issuer-specific credit risk assessment independent of general market interest rate changes.

Step-by-Step Solution

1
Differentiate between systematic and non-systematic risk factors in the scenario.
The regulatory rejection of the drug candidate is unique to the biotechnology firm (non-systematic/business/credit risk), whereas the rise in macroeconomic benchmark interest rates impacts the general economy and fixed-income market as a whole (systematic/interest rate risk).
Correct risk classification is essential to determine proper mitigation strategies and risk exposure.
2
Evaluate the risk mitigation characteristics of non-systematic risk.
Non-systematic risks, including business failure, credit downgrades, and default risk, can be effectively minimized by holding a diversified portfolio across varied industries and issuers.
Diversification neutralizes firm-specific events because bad outcomes in one issuer do not correlate across an entire portfolio.
3
Analyze the impact of credit rating downgrades versus macroeconomic interest rate movements.
The credit downgrade directly reflects heightened credit risk (default risk) specific to the firm. Conversely, price drops due to economy-wide interest rate increases represent systematic market risk, which cannot be eliminated by simply diversifying among corporate bond issuers.
Conflating interest rate risk with credit risk is a common error; interest rate risk affects all fixed-income instruments, whereas credit risk is tied to issuer creditworthiness.

Key Concept

Non-Systematic (Unsystematic) vs. Systematic Risk and Credit Risk Mitigation
Rate this question

Topics

Non-Systematic and Credit Risks

More questions from this topic